Latest Preclinical Deal for Lupus – (28th February 2013)Takeda...

Latest Preclinical Deal for Lupus – (28th February 2013)

Takeda Pharmaceutical Company (the largest pharmaceutical company in Japan) and Resolve Therapeutics (a privately held biotechnology company based in Seattle, USA) jointly announced that they have entered into a partnership to develop compounds for the treatment of lupus and other autoimmune diseases. The lead compound, RSLV-132, a novel nuclease protein, will begin clinical development later this year.

Resolve will conduct all development work under the collaboration until completion of the first RSLV-132 Phase 1b/2a trial*3 in lupus patients. Takeda has the exclusive option to license the lead compound and all other compounds from the Resolve platform upon the completion of the Phase 1b/2a trial. Upon exercise of its option, Takeda would assume lead responsibility for worldwide development and commercialization of the Resolve products.

Under the terms of the agreement, Takeda will help fund continued development of RSLV-132 through an initial payment of $8 million to Resolve in fiscal 2012. Upon exercise of its option, Takeda would pay Resolve an option exercise fee, plus the potential for additional development milestones totalling $247 million. Furthermore Resolve is eligible to receive royalties on product sales.

Lupus Belimumab (Benlysta) deal with GlaxoSmithKline - 16th July 2012

Benlysta is the first Lupus drug approved by the FDA in 50 years . Glaxosmithkline has gained full control of lupus drug Benlysta after snapping up Human Genome Sciences in a negotiated $3bn deal, following three months of hostile pursuit of its long-term US partner.
Europe's largest pharmaceutical manufacturer agreed to pay $14.25 (£9.13) a share in cash for the US biotech, which until recently had steadfastly resisted its advances. The boards of both companies have approved the deal.

Side Effects of Benlysta

The safety profile of BENLYSTA was evaluated in clinical trials. In addition to the benefits proven in these trials, BENLYSTA also has potential risks.

BENLYSTA can cause serious side effects, including infections, heart problems, and mental health problems, including suicide. Some of these side effects may cause death. However It is not known if BENLYSTA causes these serious side effects.

The most common side effects of BENLYSTA include nausea, diarrhea, fever, stuffy or runny nose, cough (bronchitis), trouble sleeping, pain in legs or arms, depression, headache (migraine), sore throat, urinary tract infection, decreased white blood cell count (leukopenia), vomiting, and stomach pain.

From the results of the previous trials carried out by Invion (ex Cbio) there have been NO side effects to date so if the Lupus trials reach their nominated primary end point what is the potential dollar value of INV03!!!!!

Exciting times ahead - watch this space.

Note - increased volumes both buying and selling and average volume now over 300,000 . The company's CEO now needs to do a road show to all potential Institutional investors to generate some real interest.